NEW YORK – Drug-discovery company ReviveMed said yesterday it is collaborating with Bristol Myers Squibb to study metabolomics for cancer immunotherapy development.
Specifically, the partners will leverage Cambridge, Massachusetts-based ReviveMed's AI-driven platform to better understand mechanisms of immunotherapy response and resistance in cancer patients.
ReviveMed uses a network-based machine learning algorithm for integrative analysis of untargeted metabolomic data with other large-scale molecular information such as data from genes, proteins, drugs, and diseases. The technology was developed in the laboratory of Ernest Fraenkel in the Massachusetts Institute of Technology Biological Engineering department.
ReviveMed said it has built a comprehensive database of metabolites and their interactions with other molecules, and the firm's AI platform uses this database to identify a large number of metabolites for individual patients at a low cost.
"We are very excited about this opportunity to work alongside industry leaders on the Bristol Myers Squibb team," ReviveMed Founder and CEO Leila Pirhaji said in a statement. "We are looking forward to discovering new biological insights through the use of artificial intelligence to characterize a large number of metabolites and integrate these data with other molecular datasets such as proteomics and genomics."
ReviveMed closed a $1.5 million seed funding round in 2018.